Science. Service. Solutions.
We are a quality and innovation-led CDMO with over 25 years of experience, committed to helping our clients deliver cell and gene therapies that transform patients? lives.
We offer end-to-end capabilities, from plasmid design and optimisation, to clinical and commercial CGMP manufacturing, accompanied by robust control systems, analytical methods and deep regulatory knowledge.
Our expertise across lentivirus, AAV, and adenoviral vectors is relied upon by some of the world?s most successful biotechnology and pharmaceutical companies.
Let's talk
>340
CGMP batches released
>50
Audits completed
>30
Process development projects
>70
Qualified assays and methods
About Oxford Biomedica
We believe in pushing the boundaries of scientific possibility and know it takes exceptional knowledge and innovative processes to make that happen.
1st worldwide to administer lentiviral vector gene therapy in vivo
1st commercial supplier of lentiviral vectors for a CAR-T therapy
Read more about us
Our cell and gene therapy services
We have extensive end-to-end capabilities in lentivirus and AAV vectors, as well as adenovirus systems and can help you design, develop, manufacture and deliver the life-changing medicines of tomorrow.
Discover our services
LentiVector ? platform
AAV platform
Tech transferred-in
LentiVector? platform
Achieve reliable and impressive results with our innovative LentiVector? platform, the first commercially approved lentiviral gene delivery technology.
LentiVector? platform
AAV platform
Bring confidence to clinical trials with our proven AAV viral vector development and production process, capable of producing consistently high quality and high titre products.
We have:
Demonstrated >E15 vg/L titers
Achieved >90% fully intact vector
Analytical toolbox with over 45 methods
Process scales from 2L to 2000L
Six successful IND/CTA filings
AAV
Tech transferred-in
Alongside our own LentiVector? and AAV platform technologies, we have the facilities and expertise to fulfil almost any development need. You define the methods and processes, and we leverage our class-leading capabilities as appropriate.
Latest

A life saving cell and gene therapy group